Phase II study to assess the impact of intermittent 1% Tenofovir Gel on Hepatitis B virus (HBV) infection

Cheryl Baxter, Salim A Abdool Karim

Abstract


A phase II randomised control trial in HBV-infected microbicide trial participants using tenofovir or placebo gel.  The impact of intermittent tenofovir gel on HBV infection in approximately 40 women by evaluating the impact of tenofovir gel on HBV DNA suppression and rebound HBV ‘flares’ and tenofovir resistance in HIV-HBV co-infected trial participants in the tenofovir arm.